Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials

Emilia Quattrocchi; Mikkel Ostergaard; Peter C. Taylor; Ronald F. van Vollenhoven; Myron Chu; Stephen Mallett; Hayley Perry; Regina Kurrasch

doi:10.1371/journal.pone.0157961

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials

Emilia Quattrocchi, Mikkel Ostergaard, Peter C. Taylor, Ronald F. van Vollenhoven, Myron Chu, Stephen Mallett, Hayley Perry, Regina Kurrasch

Institut for Klinisk Medicin

10 Citationer (Scopus)

49 Downloads (Pure)

Originalsprog	Engelsk
Artikelnummer	e0157961
Tidsskrift	PLOS ONE
Vol/bind	11
Udgave nummer	6
Antal sider	19
ISSN	1932-6203
DOI	https://doi.org/10.1371/journal.pone.0157961
Status	Udgivet - 23 jun. 2016

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1371/journal.pone.0157961Licens: CC BY

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical TrialsForlagets udgivne version, 1,15 MBLicens: CC BY

Citationsformater

Quattrocchi, E., Ostergaard, M., Taylor, P. C., van Vollenhoven, R. F., Chu, M., Mallett, S., Perry, H., & Kurrasch, R. (2016). Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials. PLOS ONE, 11(6), [e0157961]. https://doi.org/10.1371/journal.pone.0157961

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis : Results from Three Clinical Trials. / Quattrocchi, Emilia; Ostergaard, Mikkel; Taylor, Peter C. et al.

I: PLOS ONE, Bind 11, Nr. 6, e0157961, 23.06.2016.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Quattrocchi, E, Ostergaard, M, Taylor, PC, van Vollenhoven, RF, Chu, M, Mallett, S, Perry, H & Kurrasch, R 2016, 'Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials', PLOS ONE, bind 11, nr. 6, e0157961. https://doi.org/10.1371/journal.pone.0157961

@article{5199d0e52d8040ad8a62e457c09d9873,

title = "Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials",

author = "Emilia Quattrocchi and Mikkel Ostergaard and Taylor, {Peter C.} and {van Vollenhoven}, {Ronald F.} and Myron Chu and Stephen Mallett and Hayley Perry and Regina Kurrasch",

year = "2016",

month = jun,

day = "23",

doi = "10.1371/journal.pone.0157961",

language = "English",

volume = "11",

journal = "PLoS Computational Biology",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "6",

}

TY - JOUR

T1 - Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis

T2 - Results from Three Clinical Trials

AU - Quattrocchi, Emilia

AU - Ostergaard, Mikkel

AU - Taylor, Peter C.

AU - van Vollenhoven, Ronald F.

AU - Chu, Myron

AU - Mallett, Stephen

AU - Perry, Hayley

AU - Kurrasch, Regina

PY - 2016/6/23

Y1 - 2016/6/23

U2 - 10.1371/journal.pone.0157961

DO - 10.1371/journal.pone.0157961

M3 - Journal article

C2 - 27336685

SN - 1932-6203

VL - 11

JO - PLoS Computational Biology

JF - PLoS Computational Biology

IS - 6

M1 - e0157961

ER -

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater